Sujie Zheng

Sujie Zheng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in Medical Science Monitor
Verified
Journal Article
Open access
CYChunmei Ye
Chunmei Ye
WCWeiwei Chen
Weiwei Chen
QGQi Gao
Qi Gao
YCYanxia Chen
Yanxia Chen
XSXiaolu Song
Xiaolu Song
JLJinlin Liu
Jinlin Liu
Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China - Article abstract #930241

28 May 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
ZSZongjie Shi
Zongjie Shi
SGShunyuan Guo
Shunyuan Guo
JPJie Pan
Jie Pan
CXChao Xu
Chao Xu
YGYu Geng
Yu Geng
SZSujie Zheng
Sujie Zheng
Background and objective: Hyperglycemia on admission was associated with worse clinical outcomes after mechanical thrombectomy (MT) of acute ischemic stroke (AIS). We evaluated whether increased postoperative fasting glucose (PFG) was also related to poor clinical outcomes in patients who underwent MT treatment.Methods: Consecutive patients with large vessel occlusion underwent MT in our center were included. Admission glucose and fasting glucose levels after MT treatment were evaluated. Primary outcome was 90-day unfavorable outcomes (modified Rankin Scale score of 3–6). Secondary outcome was the rate of symptomatic intracranial hemorrhage (sICH) after MT treatment. The association of PFG and 90-day clinical outcome after MT treatment was determined using logistic regression analyses.Results: One hundred twenty seven patients were collected. The median postoperative fasting glucose level was 6.27 mmol/L (IQR 5.59–7.62). Fourteen patients (11.02%) had sICH, and fifty-eight patients (45.67%) had unfavorable outcomes at 90-day after MT. After adjustment for potential confounding factors, PFG level was an independent predictor of 90-day unfavorable outcome (OR 1.265; 95% CI 1.017–1.575; p = 0.035) and sICH (OR 1.523; 95% CI 1.056–2.195; p = 0.024) after MT. In addition, older age, higher baseline NIHSS score, and higher postoperative NLR were also associated with unfavorable outcomes at 90-day after MT treatment.Conclusions: Increased PFG is associated with unfavorable outcomes at 90-day and an increased risk of sICH in patients underwent MT treatment.

7 October 2025 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
SZSujie Zheng
Sujie Zheng
JHJing He
Jing He
XSXiaolu Song
Xiaolu Song
YPYe Peng
Ye Peng
WYWufeng Yuan
Wufeng Yuan
SZSujie Zheng
Sujie Zheng
Multiple myeloma (MM) remains challenging in relapsed/refractory cases due to resistance to therapies like the proteosome inhibitors or anti-CD38 antibody daratumumab (Dara). This study investigates the dual role of ALDH1A1, an aldehyde dehydrogenase implicated in drug resistance, especially in modulating daratumumab efficacy. Clinical samples from newly diagnosed multiple myeloma (NDMM) patients and in vitro studies demonstrated that ALDH1A1 expression increases consistently with the development of drug resistance to proteasome inhibitor-based chemotherapy. However, paradoxically, daratumumab-resistant non-responder relapsed/refractory MM (nrRRMM) patients showed lower ALDH1A1 expression compared to responder RRMM (rRRMM) patients. Mechanistically, ALDH1A1 enhanced CD38 expression by upregulating retinoic acid (RA), which activated the retinoid acid receptor (RAR) signaling pathway. Knockdown of ALDH1A1 in MM cell lines (H929, RPMI 8226) reduced CD38 levels, impaired daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC), and suppressed NK (natural killer) cell activity (perforin/granzyme B secretion). In contrast, RA supplement reversed declined CD38 expression caused by knocking down ALDH1A1, thereby restoring antibody-dependent cellular cytotoxicity (ADCC) efficacy. In vivo, ALDH1A1 inhibition diminished daratumumab’s antitumor effects in xenograft models, while RA co-administration reversed this resistance. These findings highlight ALDH1A1 as a context-dependent regulator: promoting chemotherapy resistance but enhancing daratumumab sensitivity via RA-CD38 axis activation. This study identifies ALDH1A1 as a predictive biomarker and proposes therapeutic strategies combining RA or ALDH1A1 modulation to overcome daratumumab resistance in RRMM.

22 January 2021 in Medicine
Verified
Journal Article
Open access
CYChunmei Ye
Chunmei Ye
JLJuan Liu
Juan Liu
XSXiaolu Song
Xiaolu Song
SZSujie Zheng
Sujie Zheng
JLJinlin Liu
Jinlin Liu
Unlike Western countries, there are still few clinical immunology specialists in China, and the optimal care for secondary immunodeficiency caused by hematological malignancies is unknown. Therefore, we initiated this clinician survey study to describe the current situation of the care for malignancy patients with hypogammaglobulinemia in China. We adapted a previously published online questionnaire of current clinical practices regarding the management of secondary immunodeficiency caused by hematological malignancies and then distributed the questionnaire to 52 hematologists in China via WeChat mobile software; the survey collected demographic details, starting dosage, target immunoglobulin (Ig) level, monitoring, criteria for stopping Ig replacement, vaccination use, and oral antibiotic prophylaxis for hypogammaglobulinemia patients. Forty-eight hematologists responded. 28(58.33%) respondents had more than 10 years of experience. Nevertheless, 40(83.33%) respondents reported that they did not use any specific criteria for prophylactic Ig replacement in hypogammaglobulinemia patients. However, 27(56.25%) respondents reported that they had used intravenous immunoglobulin (IVIG); however, the starting dose, frequency, and target Ig level were significantly varied. Additionally, the criteria for stopping Ig replacement were significantly varied. Only one respondent (2.08%) used subcutaneous immunoglobulin (SCIG). Moreover, 35(72.92%) respondents reported no vaccination prior to Ig replacement, and 47(97.92%) respondents reported that they had not used antibiotic prophylaxis in secondary hypogammaglobulinemia patients. Official guideline for the care for secondary immunodeficiency (SID) of the hematological malignancies patients should be issued in China, and significant attention of the hematologists should be paid to the use of prophylactic antibiotics and Ig replacement for the care of patients with hypogammaglobulinemia caused by hematological malignancies, as these agents could significantly reduce the infection rate in China.